Organon & Co. (NYSE:OGN) Holdings Trimmed by Carret Asset Management LLC

Carret Asset Management LLC lowered its holdings in Organon & Co. (NYSE:OGN) by 34.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,176 shares of the company’s stock after selling 29,724 shares during the period. Carret Asset Management LLC’s holdings in Organon & Co. were worth $824,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Bfsg LLC increased its holdings in shares of Organon & Co. by 78.1% in the 4th quarter. Bfsg LLC now owns 18,456 shares of the company’s stock valued at $266,000 after purchasing an additional 8,091 shares during the period. Alaska Permanent Fund Corp grew its holdings in shares of Organon & Co. by 12.3% during the 4th quarter. Alaska Permanent Fund Corp now owns 132,078 shares of the company’s stock valued at $1,905,000 after acquiring an additional 14,478 shares in the last quarter. Private Management Group Inc. increased its stake in shares of Organon & Co. by 78.5% in the fourth quarter. Private Management Group Inc. now owns 2,335,238 shares of the company’s stock worth $33,674,000 after acquiring an additional 1,027,276 shares during the last quarter. Yousif Capital Management LLC increased its stake in shares of Organon & Co. by 202.5% in the fourth quarter. Yousif Capital Management LLC now owns 105,510 shares of the company’s stock worth $1,521,000 after acquiring an additional 70,629 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new stake in shares of Organon & Co. during the fourth quarter worth $38,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

Shares of Organon & Co. stock traded down $0.32 on Thursday, reaching $18.39. The stock had a trading volume of 420,419 shares, compared to its average volume of 2,706,453. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79. The business’s 50-day moving average price is $18.14 and its two-hundred day moving average price is $15.67. The stock has a market cap of $4.70 billion, a P/E ratio of 4.68, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. As a group, equities analysts forecast that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were issued a dividend of $0.28 per share. The ex-dividend date was Friday, February 23rd. This represents a $1.12 annualized dividend and a dividend yield of 6.09%. Organon & Co.’s payout ratio is 28.00%.

Insider Activity at Organon & Co.

In other news, insider Kirke Weaver acquired 2,720 shares of Organon & Co. stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the transaction, the insider now owns 15,181 shares of the company’s stock, valued at $278,723.16. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 1.17% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised their price target on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 20th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.